Evidence map›Paper›PMID 29216273›Full record

ArticlePloS one2017

Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis.

Vidya Mave, Aarti Kinikar, Anju Kagal, Smita Nimkar, Hari Koli, Sultanat Khwaja, Renu Bharadwaj, Roy Gerona, Anita Wen, Geetha Ramachandran and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. In vivo safety evaluation method for nanomaterials for cancer therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Vidya MaveByramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.ORCID http://orcid.org/0000-0001-8509-4517
Aarti KinikarByramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
Anju KagalByramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
Smita NimkarByramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
Hari KoliByramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
Sultanat KhwajaByramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
Renu BharadwajByramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
Roy GeronaUniversity of California San Francisco, San Francisco, United States of America.
Anita WenUniversity of California San Francisco, San Francisco, United States of America.
Geetha RamachandranNational Institute of Research in Tuberculosis, Chennai, India.
Hemanth KumarNational Institute of Research in Tuberculosis, Chennai, India.
Peter BacchettiUniversity of California San Francisco, San Francisco, United States of America.
Kelly E DooleyJohns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Nikhil GupteByramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
Amita GuptaByramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India.
Monica GandhiUniversity of California San Francisco, San Francisco, United States of America.
Johns Hopkins University · USUniversity of California, San Francisco · USNational Institute of Research in Tuberculosis · IN

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)UM1AI069465 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Charles W. Flexner, Amita Gupta · 2012 to 2026
$34.1M
Plugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention TrialsR01AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA · 2012 to 2021
$5.6M
Novel methods of pharmacologic monitoring for multidrug resistant tuberculosis treatment in the setting of HIV infectionR01AI123024 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, METCALFE, JOHN ZAPATA · 2016 to 2020
$3.6M
Measuring TB Drugs in Hair as a Tool to Monitor Adherence, Exposure and Response in Patients with HIVR21AI127149 · NIAID · JOHNS HOPKINS UNIVERSITY · PI MAVE, VIDYA · 2016 to 2017
$432k
Diagnosis of active TB in HIV infected and uninfected young children in IndiaR03HD061059 · NICHD · JOHNS HOPKINS UNIVERSITY · PI JAIN, SANJAY · 2009 to 2010
$132k
NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI098472NIAID NIH HHS R01 AI123024NIAID NIH HHS R21 AI127149NIAID NIH HHS UM1 AI069465NICHD NIH HHS R03 HD061059
6 · The paper itself

Abstract

We measured hair and plasma concentrations of isoniazid among sixteen children with tuberculosis who underwent personal or video-assisted directly observed therapy and thus had 100% adherence. This study therefore defined typical isoniazid exposure parameters after two months of treatment among fully-adherent patients in both hair and plasma (plasma area under the concentration-time curve, AUC, estimated using pharmacokinetic data collected 0, 2, 4, and 6 hours after drug administration). We found that INH levels in hair among highly-adherent individuals did not correlate well with plasma AUC or trough concentrations, suggesting that each measure may provide incremental and complementary information regarding drug exposure in the context of TB treatment.

Indexed as

Antitubercular AgentsArea Under CurveChild, PreschoolHumansIsoniazidProspective StudiesTuberculosisAntitubercular AgentsIsoniazid

Identifiers

PMID29216273
PMCPMC5720757
OpenAlexW2772591054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.